Starting a biotech company requires navigating a unique intersection of science, regulation, and capital that looks nothing like launching a typical startup. The timeline from founding to generating revenue often stretches five to ten years, and the upfront costs of lab work, intellectual property, and clinical development can reach tens of millions of dollars before a product ever reaches the market. But the path is well-worn, and breaking it into concrete steps makes the process manageable.
Start With Protectable Science
Every biotech company begins with a scientific discovery or technology that can be protected. If you’re coming from academia, this usually means licensing intellectual property from your university through its technology transfer office. These negotiations cover far more than a simple fee. You’ll work through a term sheet that defines the project scope, which existing IP you’re licensing, who owns any new IP generated through collaboration, and how payments are structured. Expect to negotiate upfront fees, milestone payments tied to development progress, and royalties calculated as a percentage of net sales once a product reaches market.
Universities often show flexibility with early-stage founders who don’t have much cash. In many deals, an academic licensor will accept equity (a stake in your company) in lieu of large upfront payments. This makes the institution both a licensor and a shareholder. You’ll also need to negotiate publication rights carefully, since universities have a core mission to publish research, but your company needs time to file patents and protect its competitive position before findings become public.
If your technology isn’t coming from a university, you still need a clear IP strategy from day one. File provisional patents early, conduct freedom-to-operate searches to make sure you’re not infringing on existing patents, and budget for patent counsel. Investors will scrutinize your IP portfolio before writing a check.
Choose the Right Legal Structure
Most biotech startups that plan to raise venture capital incorporate as a Delaware C-Corporation. This structure is the standard because it allows you to issue stock, which is the primary mechanism for raising equity financing. Venture capital firms expect it, and the corporate governance framework is familiar to investors and their attorneys. Delaware specifically offers well-established business law, a specialized court system for corporate disputes, and privacy protections for company officers.
Some founders start as an LLC for the simplicity and tax advantages. LLCs offer pass-through taxation (profits flow to your personal tax return, avoiding corporate-level taxes) and require less paperwork to maintain. But if you plan to seek institutional investment, you’ll almost certainly need to convert to a C-Corp before a major funding round. That conversion costs time and legal fees, so if venture capital is in your plans, starting as a C-Corp saves a step.
Secure Early Funding Without Giving Up Equity
Before approaching venture capital firms, explore non-dilutive funding, meaning money that doesn’t require you to give away ownership in your company. The most established source for life science startups is the NIH’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant programs. Phase I awards can reach approximately $307,000, enough to fund proof-of-concept work or early feasibility studies. Phase II awards go up to roughly $2 million, which can support more extensive preclinical development.
These grants are competitive, but they validate your science in the eyes of future investors. A funded SBIR application signals that your research has passed peer review by federal scientists. Other non-dilutive sources include state-level grants, foundation funding, and disease-specific organizations that fund early research. Stack as many of these as you can before raising equity, because every dollar of non-dilutive funding preserves your ownership stake.
Raising Venture Capital
Biotech fundraising follows a staged model, with each round tied to specific milestones. At the seed stage, angel investors typically contribute $50,000 to $200,000, while venture capital firms providing seed funding may invest around $1.5 million. Investors at this stage want to see clear evidence of product-market fit: that your technology addresses a real unmet need and that there’s a definable patient population or customer base. You might demonstrate this through preclinical data, a growing patent portfolio, or letters of interest from potential partners.
Series A funding is where things scale significantly, with typical rounds just over $10 million. At this point, investors focus almost entirely on growth potential. For a therapeutic biotech, this usually means strong preclinical results, a clear regulatory path, and a management team with the experience to execute. For a tools or diagnostics company, investors want to see revenue traction or at least a pipeline of paying customers. Before you approach Series A investors, know your target market inside out and have a detailed plan for how the capital will advance your lead program to a value-inflecting milestone.
Find Affordable Lab Space
Wet lab space is expensive, and building out your own facility from scratch can easily cost millions before you run a single experiment. Biotech incubators solve this problem by offering shared lab space with essential equipment already in place. Monthly costs for a wet lab bench at an incubator run around $10,000 at facilities like the UMass Boston Venture Development Center, with memberships available month to month so you’re not locked into a long lease.
Incubators typically provide basic equipment like cell culture incubators, centrifuges, and biosafety cabinets. You’ll still need to budget for specialized instruments, consumables, and reagents specific to your work. The real value of an incubator goes beyond equipment: you’re surrounded by other biotech founders, potential collaborators, and often have access to mentorship programs and investor networks. Major biotech hubs like Boston, San Francisco, San Diego, and the Research Triangle in North Carolina all have incubator ecosystems, though new hubs are emerging in cities with strong university research programs.
Build a Regulatory Strategy Early
If you’re developing a therapeutic product, your regulatory strategy isn’t something to figure out later. It shapes your entire development plan from the start. In the United States, the critical gateway is the Investigational New Drug (IND) application, which you must file with the FDA before testing your drug in humans. The IND requires three categories of data.
First, you need animal pharmacology and toxicology studies showing that your product is reasonably safe for initial human testing. Second, you need manufacturing information demonstrating that you can produce consistent, stable batches of your drug. Third, you need detailed clinical protocols describing exactly how your proposed human trials will be conducted, along with credentials for the physicians who will oversee them and commitments to informed consent and institutional review board oversight.
Preparing an IND typically takes 12 to 18 months of preclinical work and can cost several million dollars. Many startups engage regulatory consultants early to design preclinical studies that will satisfy FDA requirements the first time, avoiding costly do-overs. The FDA also offers pre-IND meetings where you can discuss your development plan and get feedback before formally filing.
Understand the Odds at Each Stage
Biotech development is a funnel, and the numbers are sobering but important to internalize. In the earliest discovery phases, the probability of successfully moving from one stage to the next is relatively high: about 80% from target identification to finding a hit compound, 75% from hit to lead, and 85% through lead optimization. The drop-off starts in preclinical development, where roughly 69% of programs survive. Once you enter human trials, only about 54% of drugs that start Phase I will advance to Phase II, and just 34% of Phase II candidates make it through. Phase III success rates improve to around 70%, and once you submit for approval, about 91% of applications succeed.
These numbers mean that for every hundred programs that begin preclinical development, only about nine will eventually reach patients. Biotech companies and their investors build this attrition into their strategies, which is why diversified pipelines and partnership deals are so common. It’s also why raising enough capital to reach clear decision points is critical. Running out of money in the middle of a trial is the worst possible outcome.
Pharma Partnerships as a Path Forward
You don’t have to go it alone through every stage of development. Partnerships with larger pharmaceutical companies are a core part of the biotech business model and can provide both funding and expertise. These deals typically involve an upfront cash payment when the deal is signed, milestone payments triggered by development or commercial events (like starting a clinical trial or receiving regulatory approval), and royalties on eventual sales.
The size of these deals varies enormously based on the stage of your asset and the therapeutic area. Preclinical-stage deals might involve low single-digit millions upfront, while more advanced programs can command massive payments. Novartis, for example, paid $120 million upfront to Monte Rosa Therapeutics for rights to develop novel compounds for immune diseases, with total potential payments reaching $5.7 billion including milestones and royalties. Roche paid $1.65 billion upfront to Zealand Pharma for rights to an obesity drug. These are outliers, but they illustrate the value that large pharma places on promising biotech assets.
Some partnerships are structured as co-development agreements, where both companies share costs, risks, and profits. Others use an option model: the pharma company funds your early research for a relatively small fee and gains the right to license the results if the science pans out. For a small biotech, these arrangements provide capital and validation without requiring you to sell the entire company.
Assemble the Right Team
Investors fund teams as much as they fund science. At a minimum, you need deep scientific expertise in your therapeutic area, someone with drug development or regulatory experience, and a business-minded co-founder or advisor who understands fundraising and deal-making. Early-stage biotechs rarely hire all these roles as full-time employees. Instead, they rely on a combination of a small core team, scientific advisory boards made up of academic experts, and consultants for specialized functions like regulatory affairs, manufacturing, and clinical trial design.
Your scientific advisory board serves double duty: the advisors provide genuine guidance on your research program, and their names on your pitch deck signal credibility to investors. Recruit advisors who are recognized leaders in your field and compensate them with small equity grants and modest cash retainers. As you grow through seed and Series A funding, you’ll bring on full-time hires in areas where you need daily execution, typically starting with a head of research and a head of business development or operations.